CA3106669A1 - Compositions of fcrn antibodies and methods of use thereof - Google Patents

Compositions of fcrn antibodies and methods of use thereof Download PDF

Info

Publication number
CA3106669A1
CA3106669A1 CA3106669A CA3106669A CA3106669A1 CA 3106669 A1 CA3106669 A1 CA 3106669A1 CA 3106669 A CA3106669 A CA 3106669A CA 3106669 A CA3106669 A CA 3106669A CA 3106669 A1 CA3106669 A1 CA 3106669A1
Authority
CA
Canada
Prior art keywords
amino acid
seq
formulations
antibody
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3106669A
Other languages
English (en)
French (fr)
Inventor
Eva WILLIAMS
Narinder Singh
Siddhesh PATIL
Zhongli ZHANG
Gregory St. Louis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of CA3106669A1 publication Critical patent/CA3106669A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA3106669A 2018-07-20 2019-07-19 Compositions of fcrn antibodies and methods of use thereof Pending CA3106669A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701467P 2018-07-20 2018-07-20
US62/701,467 2018-07-20
PCT/US2019/042597 WO2020023310A1 (en) 2018-07-20 2019-07-19 Compositions of fcrn antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3106669A1 true CA3106669A1 (en) 2020-01-30

Family

ID=69180697

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3106669A Pending CA3106669A1 (en) 2018-07-20 2019-07-19 Compositions of fcrn antibodies and methods of use thereof

Country Status (16)

Country Link
US (1) US20210299255A1 (enExample)
EP (1) EP3826641A4 (enExample)
JP (1) JP7457704B2 (enExample)
KR (1) KR20210105872A (enExample)
CN (1) CN113301903A (enExample)
AU (1) AU2019312139B2 (enExample)
BR (1) BR112021001017A2 (enExample)
CA (1) CA3106669A1 (enExample)
CR (1) CR20210088A (enExample)
EA (1) EA202190335A1 (enExample)
IL (1) IL280280B2 (enExample)
JO (2) JOP20210015A1 (enExample)
MX (1) MX2021000790A (enExample)
PH (1) PH12021550096A1 (enExample)
SG (1) SG11202100420UA (enExample)
WO (1) WO2020023310A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64768B1 (sr) 2015-01-30 2023-11-30 Momenta Pharmaceuticals Inc Fcrn antitela i načini njihove upotrebe
KR102904658B1 (ko) 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
CN113518783A (zh) 2018-07-20 2021-10-19 动量制药公司 FcRn抗体组合物
IL302516A (en) * 2020-11-06 2023-07-01 Janssen Biotech Inc FCRN antibodies and methods of using them
US20240182598A1 (en) * 2021-04-12 2024-06-06 Momenta Pharmaceuticals, Inc. Compositions and methods for treating pediatric myasthenia gravis
WO2024163894A1 (en) 2023-02-04 2024-08-08 Momenta Pharmaceuticals, Inc. Compositions and methods for treating hemolytic disease of the fetus and newborn
CN116539488B (zh) * 2023-05-11 2023-11-24 中国食品药品检定研究院 一种体外评价生物制品稳定性的方法、系统及设备
TW202527982A (zh) 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
WO2025186787A1 (en) 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia
WO2025259928A1 (en) * 2024-06-13 2025-12-18 Obi Pharma, Inc. Improved trop2 conjugated biological molecules, pharmaceutical compositions and applications thereof
WO2026083290A1 (en) 2024-10-16 2026-04-23 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504499A (ja) * 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
CN101721362B (zh) * 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
ES2569409T3 (es) * 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
US20110027267A1 (en) * 2007-11-09 2011-02-03 Anaphore, Inc. Fusion Proteins of Mannose Binding Lectins for Treatment of Disease
WO2009124294A2 (en) 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
US20130323242A1 (en) * 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
US9844594B2 (en) * 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
RS64768B1 (sr) 2015-01-30 2023-11-30 Momenta Pharmaceuticals Inc Fcrn antitela i načini njihove upotrebe
WO2017015622A2 (en) * 2015-07-22 2017-01-26 Scholar Rock, Inc Gdf11 binding proteins and uses thereof
SMT202400004T1 (it) * 2016-07-29 2024-03-13 Momenta Pharmaceuticals Inc Anticorpi fcrn e loro metodi di utilizzo

Also Published As

Publication number Publication date
IL280280B2 (en) 2024-11-01
AU2019312139A1 (en) 2021-02-04
JP7457704B2 (ja) 2024-03-28
WO2020023310A1 (en) 2020-01-30
JP2021531346A (ja) 2021-11-18
IL280280A (en) 2021-03-25
MX2021000790A (es) 2021-07-21
JOP20210015A1 (ar) 2021-01-19
PH12021550096A1 (en) 2022-03-28
EP3826641A4 (en) 2022-04-20
IL280280B1 (en) 2024-07-01
AU2019312139B2 (en) 2025-02-06
KR20210105872A (ko) 2021-08-27
JOP20210014A1 (ar) 2021-01-19
US20210299255A1 (en) 2021-09-30
CR20210088A (es) 2021-09-02
BR112021001017A2 (pt) 2021-05-04
SG11202100420UA (en) 2021-02-25
EP3826641A1 (en) 2021-06-02
CN113301903A (zh) 2021-08-24
EA202190335A1 (ru) 2021-06-11

Similar Documents

Publication Publication Date Title
CA3106669A1 (en) Compositions of fcrn antibodies and methods of use thereof
KR102921210B1 (ko) Fcrn 항체 조성물
KR102904658B1 (ko) FcRn 항체 및 이의 사용 방법
AU2017301915B2 (en) FcRn antibodies and methods of use thereof
KR102732284B1 (ko) 등장화제로서 라이신 염을 함유하는 아플리베르셉트 제제 및 그것의 용도
IL302516A (en) FCRN antibodies and methods of using them
AU2020319897A1 (en) FcRn antibodies and methods of use thereof
TW201302223A (zh) 包含生物醫藥藥物之醫藥配方
TW202003572A (zh) 厄瑞努單抗組成物及其用途
JP2023553209A (ja) 融合タンパク質の医薬製剤
EA046994B1 (ru) КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA048285B1 (ru) Композиции антител против fcrn
CN113260627B (zh) 工程化单克隆抗体以改善稳定性和生产滴度
HK40098180A (zh) 用於融合蛋白的药物制剂
HK40002836A (en) Fcrn antibodies and methods of use thereof
HK40002836B (en) Fcrn antibodies and methods of use thereof

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241104

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250407

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250603

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250603

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260106